Minerva Neurosciences (NERV) Long-Term Debt Repayments (2014 - 2015)
Minerva Neurosciences (NERV) reported Long-Term Debt Repayments of $195656.0 for Q1 2015, down 85.85% quarter-over-quarter from $1.4 million in Q3 2014.
Minerva Neurosciences (NERV) Long-Term Debt Repayments (2014 - 2015) Analysis & Trends
Minerva Neurosciences has reported Long-Term Debt Repayments for 2 years, with the latest figure at $195656.0 in Q1 2015.
- For the quarter ending Q1 2015, Long-Term Debt Repayments changed N/A year-over-year to $195656.0; the trailing twelve-month figure through Dec 2015 stood at $195656.0 (changed N/A YoY), and the FY2015 full-year result was $195656.0, down 89.61% from the prior year.
- Long-Term Debt Repayments for Q1 2015 stood at $195656.0, down from $1.4 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $1.4 million in Q3 2014, with the low at $195656.0 in Q1 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -21,671.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Minerva Neurosciences | 197.55 Mn | 197.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | 195,656.00 |
| Mar 31, 2015 | 195,656.00 |
| Sep 30, 2014 | 1.38 Mn |
| Sep 30, 2014 | 1.38 Mn |